Page 61 - TD-1-1

Tumor Discovery Anti-PD1 for advanced pancreatic cancer

A Fortunately, immunotherapy has gradually transformed
the therapeutic landscape for various solid tumors, such
as renal cell cancer, lung cancer, melanoma, and others. In
the field of immunotherapy, many clinical trials are being
performed to test the efficacy of immunotherapy in PC, for
example, the application of adoptive cell transfer, cancer
vaccines, ICI, and combinations with molecular targeted
agents or chemoradiotherapy. It is reported that PD-L1
expression is a prognostic response to immunotherapy in
PC, so anti-PD-1 immunotherapy holds promise in the
B future treatment of PC. In addition, the combination of
cytotoxic drugs and immunotherapy seems to result in a
synergistic effect .
[12]
In this case report, we present our experiences
in treating a PC patient using surgical resection,
chemotherapy, molecular targeted medicine, and anti-PD1
immunotherapy. The combined treatment modalities
turned out to be successful in extending the patient’s
survival time to more than 6 years since diagnosis.
That being said, the application of immunotherapy in
C
combination with different therapeutic strategies might
offer a favorable treatment option for PC patients.
However, the current treatment modalities for the
treatment-associated toxicity of immunotherapy-based
approaches are limited. Even though immunotherapy
can significantly improve cancer pain and provide an
overall favorable clinical and survival benefit, the use
of immunotherapy for PC still needs to be further
[13]
investigated .
Figure 1. Imaging results. (A) Post-operative and peritoneal metastasis 4. Conclusion
in February 2018. (B) Disease progression and local recurrence in
August 2018. New nodules in the right paracolic sulcus as well as medial In this case report, we present our experiences in treating
descending colon, indicating a possible severe metastasis. Pelvic effusion a PC patient using surgical resection, chemotherapy,
and multiple lymph nodes in the abdominal cavity were roughly the same molecular targeted medicine, and anti-PD1
as before. (C) In February 2019, intraperitoneal implantation metastasis immunotherapy. The survival period of the patient was
diminished after immunotherapy was used.
successfully extended to more than 6 years since diagnosis
of PC. The combined treatments also contributed to a
3. Discussion significant decrease in CA 19-9 level. In summary, our
PC is a highly lethal malignancy with a dismal 5-year findings would be very helpful for the future studies that
survival rate . Poor tumor penetration and highly attempt to explore PC treatments in-depth.
[9]
immunosuppressive tumor microenvironment are two
major factors that limit the therapeutic efficacy of the Acknowledgments
treatment for PC. Only about 4% of patients with PC can None.
survive 5 years after diagnosis. This is due to its asymptomatic
nature, lack of reliable biomarkers, poor resectability, early Funding
[10]
metastasis, and high recurrence rate . Surgical resection This study was supported by Beijing Municipal
is the only widely accepted treatment modality for PC. Administration of Hospitals’ Youth Program
Fuerthermore, 80–85% of patients are presented with (QMS20180805), Top-notch Youth Project of the
advanced unresectable disease. Chemotherapy can be used Supporting Plan for the Construction of High-level Teachers
in those with adequate performance status, but it is not in Beijing-affiliated Universities (CIT&TCD201904093),
effective for those with poor performance status . Beijing Excellent Talents Training Funding Project
[11]

Volume 1 Issue 1 (2022) 3 https://doi.org/10.36922/td.v1i1.52